EUCTR2008-000895-25-HU进行中（未招募）不适用
A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
ovartis Vaccines and Diagnostics GmbH & Co. KG0 个研究点目标入组 334 人开始时间: 2008年5月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 334
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects aged 18 years of age and older who are mentally competent and who have signed an informed consent form after having received a detailed explanation of the study protocol;
- •2.In good health as determined by:
- •a.Medical history,
- •b.Physical examination,
- •c.Clinical judgment of the Investigator;
- •3.Able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for all study visits.
- •Informed consent must be obtained for all the subjects before enrollment into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous receipt of any H5 vaccine;
- •2.Receipt of another investigational agent within 4 weeks, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
- •3.Experienced any acute disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) within the past 7 days;
- •4.Experienced fever (defined as axillary temperature ?38.0°C) within 3 days prior to Visit 1;
- •5.Pregnant or breastfeeding;
- •6.Females of childbearing potential who refuse to use an acceptable method of birth control for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject’s study entry;
- •7.Any serious disease, such as:
- •a.Medically significant cancer,
- •b.Autoimmune disease (including rheumatoid arthritis and diabetes mellitus type 1),
- •c.Medically significant diabetes mellitus type 2,
- •d.Medically significant chronic pulmonary disease,
- •e.Medically significant acute or progressive hepatic disease,
- •f.Medically significant acute or progressive renal disease;
- •g.Medically significant acute or progressive neurological disease;
- •8.Surgery planned during the study period;
- •9.Bleeding diathesis;
- •10.Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine;
- •11.History of any neurological symptoms or signs following administration of any vaccine, or anaphylactic shock following administration of any vaccine;
- •12.Known or suspected impairment/alteration of immune function, for example, resulting from:
- •a.Receipt of immunosuppressive therapy (any systemic corticosteroid therapy or cancer chemotherapy), Inhaled and topical steroids are allowed
- •b.Receipt of immunostimulants,
- •c.High risk for developing an immunocompromising disease;
- •13.Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination;
- •14.Body Mass Index above 35 kg/m2;
- •15.History of (or current) drug or alcohol abuse that in the investigator’s opinion would interfere with safety of the subject or the evaluation of study objectives;
- •16.Any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives;
- •17.Site personnel and their relatives are excluded from participation
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1)Influenza Vaccine in Non-elderly Adult and Elderly Subjects - NDActive immunoprofilaxis against potential pandemic influenza strain.MedDRA version: 9.1Level: LLTClassification code 10059429Term: Influenza immunisationEUCTR2007-000165-38-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
进行中（未招募）
1 期
A clinical trial in adult Wilson Disease Patients to evaluate efficacy and safety of WTX101 following administration for 24 weeks with an Extension Phase of 12 MonthsWilson DiseaseMedDRA version: 18.1 Level: LLT Classification code 10047988 Term: Wilson's disease System Organ Class: 100000004850EUCTR2014-001703-41-GBWilson Therapeutics AB30
进行中（未招募）
1 期
A clinical trial in adult Wilson Disease Patients to evaluate efficacy and safety of WTX101 following administration for 24 weeks and an extension phase of 36 months.Wilson DiseaseMedDRA version: 20.0Level: LLTClassification code 10047988Term: Wilson's diseaseSystem Organ Class: 100000004850EUCTR2014-001703-41-PLWilson Therapeutics AB30
进行中（未招募）
1 期
A clinical trial in adult Wilson Disease Patients to evaluate efficacy and safety of WTX101 following administration for 24 weeks and an extension phase of 36 months.Wilson DiseaseMedDRA version: 20.0 Level: LLT Classification code 10047988 Term: Wilson's disease System Organ Class: 100000004850EUCTR2014-001703-41-ATAlexion Pharmaceuticals, Inc.30
进行中（未招募）
1 期
A clinical trial in adult Wilson Disease Patients to evaluate efficacy and safety of WTX101 following administration for 24 weeks and an extension phase of 36 months.Wilson DiseaseMedDRA version: 20.0 Level: LLT Classification code 10047988 Term: Wilson's disease System Organ Class: 100000004850EUCTR2014-001703-41-DEAlexion Pharmaceuticals, INC.30